top of page
Publications
Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human
Phase 1 SAD results demonstrated that CSTI-500, a potent triple monoamine reuptake inhibitor (TRI), achieves substantial striatal SERT occupancy and moderate DAT occupancy in healthy subjects. Combined with a favorable safety, tolerability, and pharmacokinetic profile, these findings strongly support the continued clinical development of CSTI-500.
Pubmed link here
A Phase 1, Single Center, Open-Label, Single-Dose PK and Safety Study of CSTI-500 in Prader-Willi Syndrome
Poster presentation.
"United in Hope" 2025 International PWS Conference.
A Novel Triple Monoamine Reuptake Inhibitor for The Treatment of Rare Obesity Disorders: Pharmacology of CSTI-500 and Phase 1 Clinical Trial Results
Poster presentation.
2020 Foundation for Prader-Willi Research Symposium.
bottom of page